FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553516011> ?p ?o ?g. }

• W2553516011 endingPage "5770" @default.
• W2553516011 startingPage "5770" @default.
• W2553516011 abstract "Abstract Introduction: Gene expression profiling (GEP)-defined high-risk de novo multiple myeloma (HI-MM) has a dismal prognosis with median PFS and OS stagnating at 2 and 3 years, respectively, despite the incorporation of novel agents into our Total Therapy (TT) trials. Having seen encouraging results in relapsed-refractory MM with an extended 16-day metronomic therapy (Papanikolaou, Haematologica 2014), we tested this approach in a small cohort of untreated patients with HI-MM. METRO emphasizes targeting neo-angiogenesis and other components of the bone marrow micro-environment while avoiding cytokine surges with recovering hematopoiesis following myelotoxic therapy. Patients and Methods: 10 previously untreated patients with HI-MM, who were either ineligible or unwilling for our Total Therapy protocols received a single cycle of METRO. Therapy comprised of SC bortezomib 1.0mg/m2 (0.8mg/m2 in case of grade >2 peripheral neuropathy) on days 1, 4, 7, 10, 13, 16, 19, 22, 25 and 28 schedule, PO dexamethasone 12mg (8mg in case of prior intolerance of higher dose or diabetes mellitus) on days 1 to 4, 7 to 10, 13 to 16, 19 to 22 and 25 to 28, PO Thalidomide 100mg (50mg in case of peripheral neuropathy grade >2) and continuous IV infusions of doxorubicin and cisplatin at 1.0mg/m2 daily for 28 days. Cisplatin was dose-reduced for Cr >2mg/dL and omitted for Cr >3mg/dL. Arsenic tri-oxide was given at a fixed dose of 0.01mg/kg on the days after bortezomib. Laboratory monitoring for response and toxicities were done on a Monday-Wednesday-Friday schedule. Maximal responses, based on current IMWG definitions, were measured within 30 days of completion of cycle 1, and at least monthly thereafter. KM curves were current as of 07/31/14. The Institutional Review Board granted permission for our retrospective data review, the results of which are presented here. Results: Patient characteristics included age >=65 in 8, 5 male, 5 female with ISS III in 5 patients. Metaphase cytogenetic abnormalities (CA) were detected in 7 patients. GEP70 based high risk MM was present in all 10 patients, and GEP proliferation (PR) subgroup was dominant in 8 out of 10 patients. All 10 patients achieved at least PR, including 3 qualifying for VGPR and 4 for CR. Bone Marrow responses were equally encouraging in that 8 of 10 patients qualified for complete morphologic negativity including 4 with no minimal residual disease (MRD) by 8-color flow cytometry. Of 8 patients with FDG-avid PET-CT focal lesions, 6 achieved PET-CT CR; all patients showed decreases in SUV-max and SUV-diff (background SUV). Number and/or apparent diffusion coefficient (ADC) mapping of focal lesions and background marrow on diffusion-weighted MRI improved in all 7 evaluable patients. GEP70 risk morphed from high risk to low risk in 3/4 evaluable patients. Pre and post serologic, urinary and radiologic responses are shown in Figure 1. The median follow-up time for the population was 3.2 months (98 days). All 10 patients are alive from 1 to 7 months, and 1 suffered progression (Figure 2). Overall tolerance was good. Non-hematologic grade 3/4 SEs included fatigue, electrolyte abnormalities (20%), dyspnea, hypotension, LE edema and transaminitis (10%). Conclusion: Primary 28-day metronomic therapy is highly effective and well-tolerated in patients with previously untreated HI-MM. Further prospective studies with longer follow-up are currently being devised in an attempt to improve outcomes in this population. Figure 1: Individual responses Figure 1:. Individual responses Figure 2 Figure 2. Figure 3 Figure 3. Disclosures van Rhee: Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Millenium: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees. Zangari:Norvartis: Membership on an entity's Board of Directors or advisory committees; Onyx: Research Funding; Millennium: Research Funding." @default.
• W2553516011 created "2016-11-30" @default.
• W2553516011 creator A5000879635 @default.
• W2553516011 creator A5001424327 @default.
• W2553516011 creator A5009444907 @default.
• W2553516011 creator A5015328438 @default.
• W2553516011 creator A5018694912 @default.
• W2553516011 creator A5027263046 @default.
• W2553516011 creator A5043535723 @default.
• W2553516011 creator A5082858097 @default.
• W2553516011 creator A5085020317 @default.
• W2553516011 creator A5087775484 @default.
• W2553516011 creator A5088441096 @default.
• W2553516011 creator A5090044223 @default.
• W2553516011 date "2014-12-06" @default.
• W2553516011 modified "2023-10-17" @default.
• W2553516011 title "Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study" @default.
• W2553516011 doi "https://doi.org/10.1182/blood.v124.21.5770.5770" @default.
• W2553516011 hasPublicationYear "2014" @default.
• W2553516011 type Work @default.
• W2553516011 sameAs 2553516011 @default.
• W2553516011 citedByCount "0" @default.
• W2553516011 crossrefType "journal-article" @default.
• W2553516011 hasAuthorship W2553516011A5000879635 @default.
• W2553516011 hasAuthorship W2553516011A5001424327 @default.
• W2553516011 hasAuthorship W2553516011A5009444907 @default.
• W2553516011 hasAuthorship W2553516011A5015328438 @default.
• W2553516011 hasAuthorship W2553516011A5018694912 @default.
• W2553516011 hasAuthorship W2553516011A5027263046 @default.
• W2553516011 hasAuthorship W2553516011A5043535723 @default.
• W2553516011 hasAuthorship W2553516011A5082858097 @default.
• W2553516011 hasAuthorship W2553516011A5085020317 @default.
• W2553516011 hasAuthorship W2553516011A5087775484 @default.
• W2553516011 hasAuthorship W2553516011A5088441096 @default.
• W2553516011 hasAuthorship W2553516011A5090044223 @default.
• W2553516011 hasBestOaLocation W25535160111 @default.
• W2553516011 hasConcept C126322002 @default.
• W2553516011 hasConcept C126894567 @default.
• W2553516011 hasConcept C141071460 @default.
• W2553516011 hasConcept C143998085 @default.
• W2553516011 hasConcept C2776063141 @default.
• W2553516011 hasConcept C2776364478 @default.
• W2553516011 hasConcept C2776694085 @default.
• W2553516011 hasConcept C2777063308 @default.
• W2553516011 hasConcept C2777478702 @default.
• W2553516011 hasConcept C2778283404 @default.
• W2553516011 hasConcept C2779609412 @default.
• W2553516011 hasConcept C2780007613 @default.
• W2553516011 hasConcept C2780401358 @default.
• W2553516011 hasConcept C71924100 @default.
• W2553516011 hasConcept C90924648 @default.
• W2553516011 hasConceptScore W2553516011C126322002 @default.
• W2553516011 hasConceptScore W2553516011C126894567 @default.
• W2553516011 hasConceptScore W2553516011C141071460 @default.
• W2553516011 hasConceptScore W2553516011C143998085 @default.
• W2553516011 hasConceptScore W2553516011C2776063141 @default.
• W2553516011 hasConceptScore W2553516011C2776364478 @default.
• W2553516011 hasConceptScore W2553516011C2776694085 @default.
• W2553516011 hasConceptScore W2553516011C2777063308 @default.
• W2553516011 hasConceptScore W2553516011C2777478702 @default.
• W2553516011 hasConceptScore W2553516011C2778283404 @default.
• W2553516011 hasConceptScore W2553516011C2779609412 @default.
• W2553516011 hasConceptScore W2553516011C2780007613 @default.
• W2553516011 hasConceptScore W2553516011C2780401358 @default.
• W2553516011 hasConceptScore W2553516011C71924100 @default.
• W2553516011 hasConceptScore W2553516011C90924648 @default.
• W2553516011 hasIssue "21" @default.
• W2553516011 hasLocation W25535160111 @default.
• W2553516011 hasOpenAccess W2553516011 @default.
• W2553516011 hasPrimaryLocation W25535160111 @default.
• W2553516011 hasRelatedWork W1913878759 @default.
• W2553516011 hasRelatedWork W2087887347 @default.
• W2553516011 hasRelatedWork W2128903704 @default.
• W2553516011 hasRelatedWork W2165065963 @default.
• W2553516011 hasRelatedWork W2203003885 @default.
• W2553516011 hasRelatedWork W2406204125 @default.
• W2553516011 hasRelatedWork W2530787370 @default.
• W2553516011 hasRelatedWork W2567755155 @default.
• W2553516011 hasRelatedWork W2972305086 @default.
• W2553516011 hasRelatedWork W4284886781 @default.
• W2553516011 hasVolume "124" @default.
• W2553516011 isParatext "false" @default.
• W2553516011 isRetracted "false" @default.
• W2553516011 magId "2553516011" @default.
• W2553516011 workType "article" @default.